| pubmed-article:1370332 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1370332 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:1370332 | lifeskim:mentions | umls-concept:C0153594 | lld:lifeskim |
| pubmed-article:1370332 | lifeskim:mentions | umls-concept:C1522577 | lld:lifeskim |
| pubmed-article:1370332 | lifeskim:mentions | umls-concept:C2607850 | lld:lifeskim |
| pubmed-article:1370332 | lifeskim:mentions | umls-concept:C1522326 | lld:lifeskim |
| pubmed-article:1370332 | lifeskim:mentions | umls-concept:C0205171 | lld:lifeskim |
| pubmed-article:1370332 | lifeskim:mentions | umls-concept:C0443252 | lld:lifeskim |
| pubmed-article:1370332 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:1370332 | pubmed:dateCreated | 1992-2-10 | lld:pubmed |
| pubmed-article:1370332 | pubmed:abstractText | Between 1977 and 1988, 150 patients with disseminated primary testicular germ cell tumors were treated with cisplatin, vinblastine and bleomycin. Of the 150 patients 90 (60%) achieved a complete response to chemotherapy. An additional 33 patients achieved a complete response after removal of residual masses following chemotherapy. Thus, 123 of 150 patients (82%) achieved a disease-free status following chemotherapy with or without an operation. After a median followup of 49 months the estimated long-term probability of remaining without failure and of surviving is 77%. With this data base a multivariate analysis of prognostic factors determined the Indiana University staging system to be highly predictive. Other staging systems proved to be less useful. The subset of patients with minimal and moderate disease by Indiana staging containing mature teratoma in the orchiectomy specimen has a particularly excellent prognosis (99% actuarial survival) with chemotherapy. | lld:pubmed |
| pubmed-article:1370332 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1370332 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1370332 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1370332 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:1370332 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1370332 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1370332 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1370332 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1370332 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:1370332 | pubmed:issn | 0022-5347 | lld:pubmed |
| pubmed-article:1370332 | pubmed:author | pubmed-author:CanellosG PGP | lld:pubmed |
| pubmed-article:1370332 | pubmed:author | pubmed-author:RichieJ PJP | lld:pubmed |
| pubmed-article:1370332 | pubmed:author | pubmed-author:GarnickM BMB | lld:pubmed |
| pubmed-article:1370332 | pubmed:author | pubmed-author:GibbsRR | lld:pubmed |
| pubmed-article:1370332 | pubmed:author | pubmed-author:KalishL ALA | lld:pubmed |
| pubmed-article:1370332 | pubmed:author | pubmed-author:KantoffP WPW | lld:pubmed |
| pubmed-article:1370332 | pubmed:author | pubmed-author:McDowell-Brya... | lld:pubmed |
| pubmed-article:1370332 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1370332 | pubmed:volume | 147 | lld:pubmed |
| pubmed-article:1370332 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1370332 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1370332 | pubmed:pagination | 82-8 | lld:pubmed |
| pubmed-article:1370332 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:1370332 | pubmed:meshHeading | pubmed-meshheading:1370332-... | lld:pubmed |
| pubmed-article:1370332 | pubmed:meshHeading | pubmed-meshheading:1370332-... | lld:pubmed |
| pubmed-article:1370332 | pubmed:meshHeading | pubmed-meshheading:1370332-... | lld:pubmed |
| pubmed-article:1370332 | pubmed:meshHeading | pubmed-meshheading:1370332-... | lld:pubmed |
| pubmed-article:1370332 | pubmed:meshHeading | pubmed-meshheading:1370332-... | lld:pubmed |
| pubmed-article:1370332 | pubmed:meshHeading | pubmed-meshheading:1370332-... | lld:pubmed |
| pubmed-article:1370332 | pubmed:meshHeading | pubmed-meshheading:1370332-... | lld:pubmed |
| pubmed-article:1370332 | pubmed:meshHeading | pubmed-meshheading:1370332-... | lld:pubmed |
| pubmed-article:1370332 | pubmed:meshHeading | pubmed-meshheading:1370332-... | lld:pubmed |
| pubmed-article:1370332 | pubmed:meshHeading | pubmed-meshheading:1370332-... | lld:pubmed |
| pubmed-article:1370332 | pubmed:meshHeading | pubmed-meshheading:1370332-... | lld:pubmed |
| pubmed-article:1370332 | pubmed:meshHeading | pubmed-meshheading:1370332-... | lld:pubmed |
| pubmed-article:1370332 | pubmed:meshHeading | pubmed-meshheading:1370332-... | lld:pubmed |
| pubmed-article:1370332 | pubmed:meshHeading | pubmed-meshheading:1370332-... | lld:pubmed |
| pubmed-article:1370332 | pubmed:meshHeading | pubmed-meshheading:1370332-... | lld:pubmed |
| pubmed-article:1370332 | pubmed:meshHeading | pubmed-meshheading:1370332-... | lld:pubmed |
| pubmed-article:1370332 | pubmed:year | 1992 | lld:pubmed |
| pubmed-article:1370332 | pubmed:articleTitle | Long-term followup of 150 patients with testicular cancer treated at a single institution. | lld:pubmed |
| pubmed-article:1370332 | pubmed:affiliation | Division of Clinical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115. | lld:pubmed |
| pubmed-article:1370332 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:1370332 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
